As Gilead Sciences' investigational remdesivir emerged as a promising
drug against the new coronavirus, a Chinese research institute has
applied to patent that use. Gilead's CEO Daniel O'Day said the company
doesn't plan to get into a dispute, stressing that its “responsibility is the patients.”
A paper published in The New England Journal of Medicine (NEJM) late last week described the use of the drug on the first 2019-nCoV patient in the U.S. Ten days into the illness, the patient was showing signs of pneumonia, required supplemental oxygen, suffered ongoing fevers and was positive for 2019-nCoV RNA at multiple sites.
On day 11, the physicians administered remdesivir on a compassionate use basis. The next day, the patient’s condition improved, leading to the discontinuation of supplemental oxygen and cessation of all symptoms apart from intermittent dry cough and rhinorrhea.
China-Japan Friendship Hospital plans to randomize 270 patients with mild-to-moderate pneumonia related to 2019-nCoV to receive remdesivir or placebo.
According to investigators, the phase 3 study is divided into two parts—one among mild-to-moderate pneumonia patients and the other in serious cases—and aims to enroll a total of 761 subjects. Patients will be followed for 28 days and readouts are expected as early as April.
fiercepharma
澎湃
bloomberg
NEJM's paper
pincong
A paper published in The New England Journal of Medicine (NEJM) late last week described the use of the drug on the first 2019-nCoV patient in the U.S. Ten days into the illness, the patient was showing signs of pneumonia, required supplemental oxygen, suffered ongoing fevers and was positive for 2019-nCoV RNA at multiple sites.
On day 11, the physicians administered remdesivir on a compassionate use basis. The next day, the patient’s condition improved, leading to the discontinuation of supplemental oxygen and cessation of all symptoms apart from intermittent dry cough and rhinorrhea.
China-Japan Friendship Hospital plans to randomize 270 patients with mild-to-moderate pneumonia related to 2019-nCoV to receive remdesivir or placebo.
According to investigators, the phase 3 study is divided into two parts—one among mild-to-moderate pneumonia patients and the other in serious cases—and aims to enroll a total of 761 subjects. Patients will be followed for 28 days and readouts are expected as early as April.
fiercepharma
澎湃
bloomberg
NEJM's paper
pincong
留言
張貼留言